Engineering
Immunity
TScan is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.
A history of progress
From its beginnings as a discovery-driven company to its current clinical-stage focus, TScan Therapeutics has built momentum through disciplined scientific and clinical advancement.
Building toward
patient impact
TScan is advancing engineered T cell therapy candidates from
discovery to clinical development, with a primary focus on in vivo engineering of TCR-Ts to treat solid tumors. Our programs are designed to
translate deep scientific insight into first-in-class therapies with the
potential to address unmet medical needs for patients.